Drugs / ITNK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03882840 | Jan 2019 → Jan 2028 expected | T-cell and NK-cell neoplasm | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ITNK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03882840 ↗ |
| Route | Other | “infuse the ITNK/CAR-ITNK cells back to the patients” NCT03882840 ↗ |